A prospective phase 1 study of pembrolizumab in PLWH with a CD4 count >100 cells/μl and advanced cancer demonstrated evidence of safety and activity in KS, NHL, lung cancer, and liver cancer (118). This evidence concerns the gene CD4 and non-Hodgkin lymphoma.